277 related articles for article (PubMed ID: 25714313)
1. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Krajewski KM; Nishino M; Ramaiya NH; Choueiri TK
AJR Am J Roentgenol; 2015 Mar; 204(3):W282-8. PubMed ID: 25714313
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
3. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
4. Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Hittinger M; Staehler M; Schramm N; Ubleis C; Becker C; Reiser M; Berger F
Urol Oncol; 2012 Sep; 30(5):695-703. PubMed ID: 21865061
[TBL] [Abstract][Full Text] [Related]
5. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
[TBL] [Abstract][Full Text] [Related]
6. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
[TBL] [Abstract][Full Text] [Related]
7. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
[TBL] [Abstract][Full Text] [Related]
8. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Smith AD; Lieber ML; Shah SN
AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
[TBL] [Abstract][Full Text] [Related]
9. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
11. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
[TBL] [Abstract][Full Text] [Related]
12. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
13. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
14. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Barbastefano J; Garcia JA; Elson P; Wood LS; Lane BR; Dreicer R; Campbell SC; Rini BI
BJU Int; 2010 Nov; 106(9):1266-9. PubMed ID: 20346042
[TBL] [Abstract][Full Text] [Related]
15. [Renal cell carcinoma-response criteria of molecular targeted therapy and the timing of sequential drugs in patients with advanced renal cell carcinoma].
Shinohara N
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1462-6. PubMed ID: 23064056
[TBL] [Abstract][Full Text] [Related]
16. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.
Sadeghi S; Albiges L; Wood LS; Black SL; Gilligan TD; Dreicer R; Garcia JA; Escudier BJ; Rini BI
Cancer; 2012 Jul; 118(13):3277-82. PubMed ID: 22139966
[TBL] [Abstract][Full Text] [Related]
17. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
[TBL] [Abstract][Full Text] [Related]
18. Response evaluation criteria in solid tumors response of the primary lesion in metastatic renal cell carcinomas treated with sunitinib: does the primary lesion have to be regarded as a target lesion?
Park I; Park K; Park S; Ahn Y; Ahn JH; Choi HJ; Jeong IG; Song C; Hong JH; Kim CS; Ahn H; Lee JL
Clin Genitourin Cancer; 2013 Sep; 11(3):276-82. PubMed ID: 23332873
[TBL] [Abstract][Full Text] [Related]
19. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
Basappa NS; Elson P; Golshayan AR; Wood L; Garcia JA; Dreicer R; Rini BI
Cancer; 2011 Mar; 117(6):1183-9. PubMed ID: 20960527
[TBL] [Abstract][Full Text] [Related]
20. Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b.
Lyrdal D; Stierner U; Lundstam S
Acta Oncol; 2009; 48(6):901-8. PubMed ID: 19274498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
